Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Armstrong AJ, et al. Among authors: rosbrook b. J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. J Clin Oncol. 2022. PMID: 35420921 Free PMC article. Clinical Trial.
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Rugo HS, et al. Among authors: rosbrook b. J Clin Oncol. 2011 Jun 20;29(18):2459-65. doi: 10.1200/JCO.2010.31.2975. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555686 Clinical Trial.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. Michaelson MD, et al. Among authors: rosbrook b. Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6. Oncologist. 2019. PMID: 31171735 Free PMC article. Clinical Trial.
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. Armstrong AJ, et al. Among authors: rosbrook b. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. J Clin Oncol. 2019. PMID: 31329516 Free PMC article. Clinical Trial.
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Armstrong AJ, et al. Among authors: rosbrook b. Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9. Eur Urol. 2020. PMID: 32527692 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 33157657
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Armstrong AJ, et al. Among authors: rosbrook b. J Urol. 2021 May;205(5):1361-1371. doi: 10.1097/JU.0000000000001568. Epub 2020 Dec 28. J Urol. 2021. PMID: 33356529 Clinical Trial.
Reply by Authors.
Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Armstrong AJ, et al. Among authors: rosbrook b. J Urol. 2021 May;205(5):1371. doi: 10.1097/JU.0000000000001568.02. Epub 2021 Mar 11. J Urol. 2021. PMID: 33705222 No abstract available.
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong AJ, Rosbrook B, Sugg J, Baron B, Chen L, Kunieda F, Stenzl A. Iguchi T, et al. Among authors: rosbrook b. Int J Urol. 2021 Jul;28(7):765-773. doi: 10.1111/iju.14568. Epub 2021 May 6. Int J Urol. 2021. PMID: 33955599 Free PMC article. Clinical Trial.
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND. Freedland SJ, et al. Among authors: rosbrook b. BMJ Open. 2021 Aug 12;11(8):e046588. doi: 10.1136/bmjopen-2020-046588. BMJ Open. 2021. PMID: 34385241 Free PMC article. Clinical Trial.
68 results